Low-dose radiation and chemoimmunotherapy for NPC with liver spread
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for nasopharyngeal cancer that has spread to the liver. It aims to see if this approach can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old and not pregnant if female.
- You have a type of nasopharyngeal cancer that has spread to the liver (either newly diagnosed or came back more than 6 months after prior treatment).
- You are in generally good health (able to do daily activities without help) and have normal blood counts and organ function.
- You have not had prior immunotherapy (like checkpoint inhibitors) for this cancer.
- You do not have active autoimmune disease, uncontrolled diabetes, serious infections, or other cancers in the last few years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
This trial tests a new treatment for nasopharyngeal cancer that adds an immune-boosting drug (toripalimab) before and after radiation therapy, while skipping radiation to the neck lymph nodes. It aims to see if this approach is effective and reduces side effects.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This study looks at how the immune system responds to radiation therapy for nasopharyngeal cancer. It will use scans and blood tests to find markers that might predict how well treatment works.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.